HIV-1 infection and CCR5∆32 homozygosis

Author： Ballana Ester   Esté José A  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.7, Iss.7, 2012-07, pp. : 653-658

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CCR5 Chemokine Receptors: Gatekeepers of HIV-1 Infection

By  

Current Drug Targets - Infectious Disorders, Vol. 2, Iss. 3, 2002-09 ,pp. : 265-278

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of HIV infection with the CCR5 antagonist maraviroc

By Kromdijk Wiete   Huitema Alwin DR   Mulder Jan Willem  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1215-1223

Informa Healthcare

Access to resources Recommend Favorite

The CCR5 receptor antagonist maraviroc reduces viral load in patients with HIV-1 infection

By  

Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Maraviroc: A Review of its Use in the Management of CCR5-Tropic HIV-1 Infection

By Perry Caroline M.  

Drugs, Vol. 70, Iss. 9, 2010-06 ,pp. : 1189-1213

Adis International

Access to resources Recommend Favorite

Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection

By Caldwell David J   Evans Jeffery D  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 18, 2008-12 ,pp. : 3231-3242

Informa Healthcare

Access to resources Recommend Favorite